Cytodyn OTC Stock Insiders
| CYDY Stock | USD 0.11 0.01 8.33% |
Cytodyn employs about 23 people. The company is managed by 7 executives with a total tenure of roughly 10 years, averaging almost 1.0 years of service per executive, having 3.29 employees per reported executive. Break down of Cytodyn's management performance can provide insight into the company performance.
| Denis Burger Chairman Vice Chairman and Chief Science Officer |
Cytodyn |
Cytodyn Management Team Effectiveness
The company has return on total asset (ROA) of (1.4819) % which means that it has lost $1.4819 on every $100 spent on assets. This is way below average. Cytodyn's management efficiency ratios could be used to measure how well Cytodyn manages its routine affairs as well as how well it operates its assets and liabilities.Cytodyn Workforce Comparison
Cytodyn is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,054. Cytodyn holds roughly 23.0 in number of employees claiming about 2.18% of equities under Health Care industry.
Cytodyn Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cytodyn Price Series Summation is a cross summation of Cytodyn price series and its benchmark/peer.
Cytodyn Notable Stakeholders
A Cytodyn stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cytodyn often face trade-offs trying to please all of them. Cytodyn's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cytodyn's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Denis Burger | Vice Chairman and Chief Science Officer | Profile | |
| Bernie PMP | VP Operations | Profile | |
| George Bitar | Head Director | Profile | |
| Antonio CPA | Treasurer CFO | Profile | |
| Kush Dhody | VP Operations | Profile | |
| Cyrus MBA | President | Profile | |
| Cristina Leon | Investors | Profile |
About Cytodyn Management Performance
The success or failure of an entity such as Cytodyn often depends on how effective the management is. Cytodyn management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cytodyn management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cytodyn management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.
The data published in Cytodyn's official financial statements typically reflect Cytodyn's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Cytodyn's quantitative information. For example, before you start analyzing numbers published by Cytodyn accountants, it's essential to understand Cytodyn's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Cytodyn's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cytodyn. Check Cytodyn's Beneish M Score to see the likelihood of Cytodyn's management manipulating its earnings.
Cytodyn Workforce Analysis
Traditionally, organizations such as Cytodyn use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cytodyn within its industry.Cytodyn Manpower Efficiency
Return on Cytodyn Manpower
| Revenue Per Employee | 11.6K | |
| Revenue Per Executive | 38K | |
| Net Loss Per Employee | 9.2M | |
| Net Loss Per Executive | 30.1M |
Additional Tools for Cytodyn OTC Stock Analysis
When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.